INTRODUCTION

43
Hsp90 is a highly abundant molecular chaperone, including in non-stressed cells, 44 which is required for the maturation, stability, activity, and/or degradation of a 45 substantial portion of the proteome (1-5; for a regularly updated list of Hsp90 46 interactors, see http://www.picard.ch/downloads/Hsp90interactors.pdf). To its clients, 47
Proteomics. iTRAQ experiments were carried out and analyzed as described (35, 166 36) . Protein extracts processed as described (33) 
RESULTS
180
Complex expression pattern of Aarsd1. There are eight spliced transcripts for the 181 mouse Aarsd1 gene in databases such as Ensembl (www.ensembl.org) (Fig. 1B) . 182
According to the database Uniprot (www.uniprot.org), transcripts 2 and 3 encode a 183 putative and an annotated and existing protein, respectively. Transcripts 3 and 4 are 184 additionally annotated in the highly curated database of the "Consensus CDS 185 project" (CCDS, http://www.ncbi.nlm.nih.gov/CCDS). Based on our own extensive 186
RT-PCR and immunoblotting experiments (Figs. 1C and 2), we conclude that a short 187 form, here denoted Aarsd1S, is the protein product of transcript 4, and corresponds 188 to what was previously referred to as tsp23 (28) or p23 H (29) . The CS domain is 189 encoded by exons 1 to 4 and in the case of Aarsd1S, the coding sequence extends9 (40 amino acids out of a total of 131) through exon 5 and into the very beginning of 191 exon 8. We recapitulated the ying-yang expression pattern relative to p23 in the 192 muscle that had been previously found (28), and in fact not only for Aarsd1S, but 193 also for the long protein product Aarsd1L of transcript 1 (Figs. 1 and 2 ). Intriguingly 194 and as reported before (34), Hsp90α, one of the two cytosolic Hsp90 isoforms, 195 displays an expression pattern in mouse tissues that is inversely correlated with the 196 muscle-specific forms of Aarsd1, being essentially absent in heart and skeletal 197 muscle ( Fig. 2A) . Thus, the increased muscle-specific expression of some variants of 198 the putative Hsp90 co-chaperone Aarsd1, the loss of p23, and a remarkable Hsp90 199 isoform switch indicate that the Hsp90 ensemble is substantially remodeled in 200 muscle relative to other tissues. 201
202
To allow us to manipulate this remodeled Hsp90 ensemble experimentally, we 203 decided to explore a cell culture system for muscle differentiation. Immortalized 204 mouse C2C12 cells proliferate as myoblasts in high-serum conditions; once they 205 become confluent and are switched to low serum, they fuse and differentiate into 206 twitching myotubes (Fig. 2B) . A qualitative survey by RT-PCR of the expression of all 207 the Aarsd1 splice variants shows that only some of them are detectable at all (Fig. 208 1D). Only transcripts 1, 3, 4, 5 and 6 are detectable during C2C12 differentiation. 209
The splice variants Aarsd1L (encoded by transcript 1) and Aarsd1S (encoded by 210 transcript 4) appear in the final stages of differentiation to myotubes, mirroring their 211 tissue distribution in the adult mouse (Fig. 2) . In contrast, the levels of Aarsd1M 212 (encoded by transcript 3) remain constant throughout the C2C12 differentiation 213
program, a pattern that is consistent with the ubiquitious expression of this splice 214 variant across mouse tissues (Fig. 2) . As for Aarsd1, the C2C12 system faithfully 215 recapitulates the Hsp90 isoform switch. While Hsp90β remains constant, Hsp90α 216 disappears as C2C12 cells differentiate into myotubes (Fig. 2C) . Hence, the 217 remodeling of the Hsp90 ensemble does happen in differentiating C2C12 cells as it 218 must happen during muscle differentiation in the mouse. These findings establish 219 C2C12 cells as a valid cell culture system for further functional analyses. 220 221 Aarsd1L interacts exclusively with Hsp90β and competes with p23 for binding. 222
The fact that Aarsd1L shares a CS domain with known Hsp90 co-chaperones such 223 as p23, and is expressed in skeletal muscle, where p23 is absent, led us to evaluate 224 its ability to interact with Hsp90 and potentially to replace p23. Fig. 3A shows that an 225 HA-tagged version of Aarsd1L, exogenously expressed in human HEK 293T or HeLa 226 cells, can co-immunoprecipitate Hsp90. Remarkably, only the Hsp90β isoform but 227 not Hsp90α is associated with Aarsd1L. Note that this experiment was done in cells 228 that express both, but that Hsp90β happens to be the only cytosolic Hsp90 isoform 229 present in differentiated muscle. Using the same assay, we determined that the C-230 terminal domain comprising the AlaXp domain is dispensable and the CS domain 231 sufficient (mutant Aarsd1L∆C) for binding Hsp90β (Fig. 3B ). Aarsd1L∆C essentially 232 corresponds to the splice variant Aarsd1S, except that the mutant lacks the C-233 terminal 18 amino acids of the splice isoform. It is therefore safe to assume that 234 Aarsd1S binds Hsp90 as well. Within the CS domain, we found a conserved 235 tryptophan, known to be critical in p23 for Hsp90 binding (37, 38) , to be essential as 236 well (mutant W107A). Considering that Aarsd1 appears to bind Hsp90 through its CS 237 domain, we reasoned that it might compete with p23. Indeed, increasing 238 concentrations of transiently expressed Aarsd1L prevent the co-immunoprecipitationperformed with lysates of mouse skeletal muscle tissue confirmed the association for 241 endogenous Hsp90β and Aarsd1L (Fig. 3D) is required for full repression of GR activity. While the result with the ∆C mutant is 271 compatible with the modest stimulatory effect that had been found for tsp23, an 272
Aarsd1 form equivalent to ∆C/Aarsd1S (28), it remains to be seen whether there is 273 anything specific about the C-terminal AlaXp domain that is required or whether it is 274 just the juxtaposition of the Aarsd1 CS domain with a large C-terminal moiety. 275 276 These assays were done at a constant, but relatively low concentration of Dex (10 277 nM). When we compared the inhibitory effects of wild-type Aarsd1L and of two key 278 mutants (∆C and W107A) at this concentration with those at subsaturating (1 nM) 279 and almost saturating (100 nM) concentrations of Dex, we essentially saw the same 280 pattern (Fig. 4C) . As an additional read-out of the impact of the Hsp90-p23 281 machinery on GR activity, we looked at the hormone-induced nuclear localization of 282 GR (45). As a visualization tool, we used Tom.GR, a fusion between the red 283 fluorescent protein tomato and GR; at non-saturating concentrations of the synthetic 284 glucocorticoid Dex, a time-course of nuclear localization of Tom.GR provides a 285 simple qualitative assay for Hsp90 complex-assisted GR functionality (33). Fig. 5  286 shows that Aarsd1L, but not p23, slows down nuclear localization of Tom.GR. 287
288
Overall, these results suggest that Aarsd1L interferes with efficient GR maturation by 289 the Hsp90 machinery. Although not tested at even higher concentrations, it appears 290 that Aarsd1L mostly affects the maximal induction (efficacy) rather than the apparent 291 affinity (potency). An altered efficacy can be an indication for a mechanism that 292 affects post-maturation events such as the dynamic and Hsp90-independent 293 recycling of GR transactivation complexes by p23 at the chromatin (28). We formally 294 cannot exclude that Aarsd1L, similarly to p23, intervenes both during maturation and 295 after activation of GR. However, considering that the Hsp90-binding mutant W107A 296 is at least partially defective for GR repression (Fig. 4) and that the effect is inhibitory 297 rather than stimulatory as previously reported for p23 and tsp23 (Aarsd1S ~ ∆C) 298 (28), it seems more likely that Aarsd1L acts primarily as a novel Hsp90 co-chaperone 299 upstream of GR activation by hormone. 300
301
Aarsd1 is required for myotube differentiation and protects against symptoms 302 reminiscent of glucocorticoid-induced muscle wasting. To investigate the 303 functional relevance of the muscle-specific expression of some Aarsd1 splice 304 variants, we set out to knock down and overexpress the long form Aarsd1L, which is 305 the one with the most pronounced differentiation-specific expression pattern ( Aarsd1 transcripts affected primarily the expression of the two muscle-specific forms 309 (lanes 8 and 9) and transfecting myoblasts with an expression vector for HA-tagged 310 Aarsd1L led to the expression of exogenous levels roughly matching those of the 311 endogenous protein (lanes 10 and 11). The most striking impact of the Aarsd1 312 knock-down is a severe inhibition of myotube differentiation (Fig. 6B) , which is 313 accompanied by a strong reduction of the muscle marker myosin heavy chain (Fig. 314 affect myotube differentiation; upon overexpressing Aarsd1L, a slight increase in 316 myosin heavy chains may be associated with an increase in degradation products 317 (lanes 10 and 11), suggesting that too much Aarsd1L may also be detrimental for the 318 proper maturation and/or stability of this muscle marker. 319 320 Considering that Aarsd1L was able to repress GR activity in heterologous cells, we 321 wondered whether Aarsd1L could mitigate the negative effects of glucocorticoids in 322 muscle cells. To this end, we first determined for the C2C12 system what parameters 323 could be used as a surrogate for glucocorticoid-induced muscle wasting. We 324 examined the impact of GR activity on the expression of Klf15, a direct target gene 325 encoding a transcription factor and key mediator of glucocorticoid-induced muscle 326 wasting (46). Upon treating myotubes with Dex for 24 hours, we could see induction 327 of Klf15 by immunoblotting ( Fig. 6A ; lane 7); while the induction was modest at the 328 protein level, it was substantial at the mRNA level (Fig. 6C ). Although the levels of 329 myosin heavy chains increased, so did the amounts of degradation products (lane 7). 330
Dex treatment significantly decreased the number of differentiated myotubes. Having 331 established these features as a read-out, we analyzed the impact of Aarsd1L 332 overexpression (Fig. 6 ). We found that Aarsd1L overexpression prevented the 333 induction of Klf15 at the protein and mRNA levels ( well-known GR target gene, was similarly impaired by Aarsd1L overexpression (Fig.  336   6C ). In contrast, the impact of Dex on the "quality" of myosin heavy chains could not 337 be rescued (Fig. 6A , lane 11), possibly for the same reasons already suggested 338 above. Overall, these results support the hypothesis that Aarsd1L dampens GR 339 activity and thereby contributes to protecting muscle cells against the toxic effects of 340
glucocorticoids. 341 342
The Hsp90 isoform switch is essential for myotube differentiation. Our 343 observation that myotube differentiation is associated with a striking Hsp90 isoform 344 switch raised the question whether this switch is required to allow or even to promote 345 the differentiation program. To address this question, we overexpressed Hsp90α by 346 transfecting C2C12 myoblasts before differentiation. This essentially maintained 347 constant levels of Hsp90α throughout the differentiation program (Fig. 7A) . The 348 overexpression of Hsp90α specifically affected the quality of myosin, as indicated by 349 an increase in ubiquitinated species and degradation products (Fig. 7A) , and 350 severely delayed the formation of myotubes over the course of the experiment (Fig.  351   7B ). In contrast, overexpression of Hsp90β did not affect myotube formation ( Fig.  352   7C) ; moreover, although a slight reduction in the abundance of Hsp90β was 353 observed upon overexpression of Hsp90α (Fig. 7A) , overexpressing Hsp90β 354 together with Hsp90α only minimally counteracted the inhibitory effects of Hsp90α 355 overexpression (Fig. 7C) . Thus, maintaining the presence of Hsp90α during muscle 356 differentiation seems to be detrimental for this process. 357
358
A large fraction of proteins affected by Hsp90 inhibition are involved in the 359
muscle-specific differentiation program. We speculate that the remodeling of the 360 Hsp90 ensemble improves its ability to handle certain proteins linked to muscle 361 differentiation. As a first step towards gaining a better understanding of what these 362 proteins might be, we undertook a proteomic analysis of the changes that occur 363 during differentiation and of the impact of inhibiting Hsp90 pharmacologically. Thecontinuous treatment of C2C12 cells during differentiation to myotubes with a low 365 dose of geldanamycin (GA; 10 nM) completely abolishes the formation of myotubes 366 (Fig. 8) , confirming previous reports (47) and setting the stage for our proteomic 367 investigation. The comparison of the proteomes of C2C12 myoblasts and myotubes 368 by mass spectrometry showed substantial changes. Applying a 1.2-fold change as a 369 cut-off, we found that 761 proteins are up-regulated and 871 down-regulated (Fig. 9A  370 and Table S1 in the supplemental material). We then treated differentiated myotubes 371 with GA for 24 hours using 500 nM, which we had previously determined to kill 25% 372 of the cells (IC25). This GA treatment up-regulated and down-regulated 353 and 329 373 proteins, respectively (Table S2 in the supplemental material). The comparison of the 374 proteins that are up-regulated during myotube differentiation (761) with those that go 375 down upon inhibiting Hsp90 (329) reveals a large overlap (Fig. 9B ). The analysis of 376 these sets of proteins according to gene ontologies (GO) indicates a strong 377 functional enrichment for proteins involved in muscle development. Whereas this 378 may be expected for the proteins whose levels change upon C2C12 differentiation 379 (Fig. 9A) , it is particularly striking for those affected by GA, and indeed most strongly 380 for those proteins up-regulated by differentiation and down-regulated by GA 381 treatment (Fig. 9B) (28, 34, (48) (49) (50) , presumably to meet 391 its highly specific needs during the final stages of differentiation and for function and 392 tissue homeostasis. For the Hsp90 ensemble, the remodeling is substantial. While 393 this was already apparent from comparing muscle to other tissues, our analysis with 394 the C2C12 cell model provides an insight into the dynamic remodeling of the 395 ensemble during the differentiation process. The changes include the disappearance 396 of one of the two cytosolic Hsp90 isoforms and p23, and the appearance of new 397
Hsp90 co-chaperones. Our knock-down and overexpression experiments provide 398 evidence that the switch to Hsp90β and the induction of the long form of Aarsd1L are 399 a requirement for myotube differentiation to proceed normally. Thus, the remodeling 400 of the Hsp90 ensemble accompanies and drives muscle differentiation (Fig. 10) . AlaXp domain. Be that as it may, this exquisite Hsp90β-specificity is highly 444 reminiscent of that of another co-chaperone. Unc45a (also known as GC-UNC45) 445 has been shown to bind Hsp90β preferentially (53, 54). Strange enough, while 446 Unc45a is ubiquitously expressed and largely persists in differentiating C2C12 cells 447 (48), the muscle-specific isoform Unc45b (48) appears to bind Hsp90 without 448 isoform-specificity (13). Nevertheless, it is noteworthy that Unc45 had been linked to 449 muscle differentiation and myosin assembly in the nematode C. elegans (55, 56), an 450 organism that has p23 but no Aarsd1 ortholog. Moreover, in an unc45 mutant of the 451 same organism, Hsp90 and other co-chaperones are required for muscle integrity 452 and motility (57). 453
454
The C2C12 system will provide a powerful system in which to study isoform-455 selectivity and the requirements of particular Hsp90 clients for the muscle-specifically 456 remodeled Hsp90 ensemble. Our proteomic analysis suggests a number of relevant 457 Hsp90 clients other than GR. It will be very interesting to investigate the muscle-458 specific factors that are affected by Hsp90 inhibition and to determine to what extent 459 they are dependent on the remodeling of the Hsp90 ensemble, i.e. the presence of 460 muscle-specific co-chaperones such as Aarsd1L and Unc45 and whether they 461 display a preferential dependence on Hsp90β over Hsp90α. n/a n/a n/a n/a n/a 
